Last updated: September 3, 2026
Nitrofurantoin macrocrystalline is a mature, low-cost generic antibacterial used primarily for uncomplicated urinary tract infections. Its commercial profile is driven by prescription volume, manufacturing reliability and reimbursement access rather than patent exclusivity. The product has no meaningful remaining branded patent barrier in the United States, and generic competition is established. Financial upside is limited by low pricing, but demand remains durable because of clinical use in lower urinary tract infections and resistance-management preferences.
What is nitrofurantoin macrocrystalline?
Nitrofurantoin macrocrystalline is the active ingredient in Macrodantin and equivalent generic capsules. It is supplied in 25 mg, 50 mg and 100 mg strengths. The macrocrystalline form has a slower dissolution profile than older nitrofurantoin formulations and was developed in part to improve gastrointestinal tolerability.
The drug is indicated for treatment or prophylaxis of urinary tract infections caused by susceptible organisms. It is not appropriate for pyelonephritis or systemic infections because tissue and serum concentrations are inadequate for those uses.[1]
Nitrofurantoin is marketed in several distinct product configurations:
| Product |
Composition |
Typical dosing pattern |
Commercial position |
| Nitrofurantoin macrocrystals |
Macrocrystalline nitrofurantoin |
Usually four times daily |
Mature generic |
| Macrodantin |
Nitrofurantoin macrocrystals |
Usually four times daily |
Legacy reference brand |
| Nitrofurantoin monohydrate/macrocrystals |
25% monohydrate and 75% macrocrystals |
Usually twice daily |
Macrobid and generic equivalents |
| Macrobid |
Nitrofurantoin monohydrate/macrocrystals |
100 mg twice daily |
Higher-convenience branded formulation |
Macrodantin and Macrobid are not interchangeable on a milligram-for-milligram formulation basis. Macrobid contains a combination of monohydrate and macrocrystalline material, while nitrofurantoin macrocrystals contains the macrocrystalline form alone.[2]
What is the FDA regulatory status of nitrofurantoin macrocrystalline?
Nitrofurantoin macrocrystalline is an FDA-approved immediate-release oral capsule product with a long-established reference product. Generic versions are approved through abbreviated new drug applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act.
The reference product Macrodantin was approved under NDA 016812. The product is not a biologic, so biosimilar regulation does not apply. Generic manufacturers must demonstrate pharmaceutical equivalence and bioequivalence rather than conduct biosimilar comparability studies.
The main regulatory characteristics are:
- FDA approval as an oral capsule.
- ANDA-based generic competition.
- No FDA biologic-license or biosimilar pathway.
- No practical pediatric exclusivity or new-chemical-entity exclusivity remaining.
- Established safety labeling, including pulmonary, hepatic, neurologic and hemolytic-anemia warnings.
- Renal-function restrictions that limit use in patients with materially reduced kidney function.[1]
The FDA label identifies nitrofurantoin as appropriate for lower urinary tract infection treatment and prevention when the causative organism is susceptible. The label also states that the drug should not be used for pyelonephritis because it does not achieve adequate renal tissue concentrations.[1]
What is the Orange Book status of nitrofurantoin macrocrystalline?
Nitrofurantoin macrocrystalline has no commercially important active Orange Book patent exclusivity protecting the underlying molecule, macrocrystalline form or standard capsule presentation. The drug is a mature small-molecule generic with long-expired composition and formulation protection.
The Orange Book remains relevant for confirming:
- The reference listed drug.
- Approved dosage forms and strengths.
- Generic approval status.
- Any patent or regulatory-exclusivity entries associated with the reference product.
For a standard nitrofurantoin macrocrystal capsule, the principal market-access issue is ANDA approval and supply capability, not branded patent enforcement. The Orange Book does not create a continuing market monopoly for the reference product.[3]
Does nitrofurantoin macrocrystalline have active patents?
No material U.S. patent barrier is expected to block ordinary generic entry for nitrofurantoin macrocrystalline capsules. The foundational nitrofurantoin patents and early formulation rights expired decades ago.
Potentially relevant patent categories include:
| Patent category |
Current commercial significance |
| Nitrofurantoin active ingredient |
Expired |
| Macrocrystalline particle form |
Expired or no longer commercially blocking |
| Standard capsule formulation |
Expired |
| Macrodantin product claims |
No meaningful remaining exclusivity |
| Manufacturing process claims |
May exist in isolated jurisdictions but do not create broad U.S. market exclusivity |
| New delivery systems |
Potentially relevant only if a distinct product is developed |
Patent families covering specific manufacturing techniques, particle-size controls, excipients or delivery systems can have technical value. They do not generally prevent approval of conventional macrocrystalline capsules unless a generic product practices the claimed process or formulation.
When does nitrofurantoin macrocrystalline lose exclusivity?
Nitrofurantoin macrocrystalline lost effective market exclusivity many years ago. The product is now in the mature generic phase.
| Exclusivity type |
Status |
| New chemical entity exclusivity |
Expired |
| Original formulation exclusivity |
Expired |
| Pediatric exclusivity |
Not commercially relevant |
| Orphan-drug exclusivity |
Not applicable |
| Reference-product patent exclusivity |
No material active barrier expected |
| Generic competition |
Established |
The relevant commercial date is therefore not a future patent-expiration date. Revenue is determined by generic competition, payer contracting, channel inventory and supply continuity.
How many patents cover nitrofurantoin macrocrystalline?
No meaningful number of active U.S. patents is expected to cover the conventional drug product as a broad market category. Patent counting is less useful for this product than for recently launched branded medicines because:
- The molecule is old.
- The macrocrystalline product has been commercialized for decades.
- Generic manufacturers have already obtained approvals.
- Any surviving process or formulation claims would have narrower scope than the reference product’s original protection.
A patent landscape may identify isolated historical or jurisdiction-specific claims, but those claims should not be treated as a broad barrier to U.S. generic supply without claim-by-claim infringement analysis.
Are there Paragraph IV challenges for nitrofurantoin macrocrystalline?
Paragraph IV litigation is not a central market feature for nitrofurantoin macrocrystalline. A Paragraph IV certification is relevant when an ANDA applicant seeks approval before expiration of an Orange Book-listed patent. Because the conventional product has no material remaining patent estate, generic applicants can generally rely on a paragraph III certification, a section viii statement where appropriate, or the absence of an applicable listed patent.
The practical risk profile is:
| Litigation issue |
Assessment |
| Paragraph IV litigation against the core macrocrystalline capsule |
Low |
| ANDA approval delay from listed patents |
Low |
| Method-of-use patent risk |
Low for the standard labeled indication |
| Formulation-patent risk |
Low for the legacy capsule |
| Trade-secret or process litigation |
Possible but narrow |
| Antitrust or reverse-payment exposure |
Not a central current issue |
No active, high-value U.S. litigation campaign is broadly associated with the conventional nitrofurantoin macrocrystalline capsule.
What formulation patents protect nitrofurantoin products?
The main formulation distinction is between macrocrystalline nitrofurantoin and the monohydrate/macrocrystal combination used in Macrobid. Formulation differentiation can affect dosing frequency, dissolution, tolerability and substitution status.
Macrobid’s commercial value came from its twice-daily dosing format, not from a new antibiotic molecule. Its formulation contains 100 mg of nitrofurantoin as 25 mg monohydrate and 75 mg macrocrystals.[2]
Potential formulation-protection strategies for future products could include:
- Controlled-release capsules.
- Reduced-frequency dosing.
- Modified particle-size distributions.
- Gastrointestinal tolerability improvements.
- Extended stability under temperature or humidity stress.
- Alternative oral dosage forms.
- Combination products or targeted urinary delivery.
These concepts may support a new patent filing if they produce a non-obvious technical result. They would not restore exclusivity to ordinary nitrofurantoin macrocrystals.
What method-of-use patents cover nitrofurantoin macrocrystalline?
Method-of-use patent value is limited because the principal indication, uncomplicated lower urinary tract infection, is long established. A new patent would need to claim a sufficiently distinct use, dosing regimen, patient population or clinical outcome.
Potential areas of differentiated use include:
- Prophylaxis in a defined recurrent-UTI population.
- Renal-function-specific dosing.
- Use in a genetically or microbiologically defined subgroup.
- A new treatment duration supported by clinical evidence.
- Combination treatment for a defined resistant pathogen.
Broad claims covering treatment of ordinary susceptible urinary tract infections would face substantial validity and prior-art risk. The current label and prescribing information do not create a meaningful method-of-use monopoly for the conventional product.[1]
Which companies manufacture nitrofurantoin macrocrystalline?
Nitrofurantoin macrocrystalline has been supplied by multiple generic manufacturers and contract manufacturers over time. Product availability can vary by strength, packaging configuration, supplier and wholesaler inventory.
The competitive field typically includes:
- Established U.S. generic companies.
- Indian and European API suppliers.
- Contract manufacturing organizations.
- Specialty generic companies with limited product portfolios.
- Distributors sourcing from multiple approved manufacturers.
Manufacturers must manage API sourcing, particle-size consistency, capsule filling, dissolution performance, stability and FDA facility compliance. Because the product has low unit value, manufacturing economics favor efficient high-volume production rather than expensive differentiated development.
A supplier may gain share during a temporary shortage, but that advantage often reverses when competing manufacturers restore inventory. The market is therefore vulnerable to abrupt price and volume changes caused by manufacturing interruptions.
What is the competitive landscape for nitrofurantoin macrocrystalline?
Nitrofurantoin competes with other oral agents used for uncomplicated urinary tract infections, including trimethoprim-sulfamethoxazole, fosfomycin and selected beta-lactams. The competitive decision depends on local resistance patterns, patient allergies, renal function, pregnancy considerations, infection severity and prescriber preference.
| Competitor |
Primary commercial advantage |
Principal limitation |
| Nitrofurantoin macrocrystals |
Low cost and continued utility against many urinary pathogens |
Frequent dosing; unsuitable for upper-tract infection |
| Nitrofurantoin monohydrate/macrocrystals |
Twice-daily convenience |
Higher formulation complexity and generic competition |
| Fosfomycin |
Single-dose treatment in many uncomplicated cases |
Higher acquisition cost and variable availability |
| Trimethoprim-sulfamethoxazole |
Familiar, low-cost oral therapy |
Resistance and allergy constraints |
| Oral beta-lactams |
Broad prescriber familiarity |
Often lower efficacy for uncomplicated cystitis and longer courses |
Guideline preferences have supported nitrofurantoin use in uncomplicated cystitis when clinically appropriate. The Infectious Diseases Society of America has identified nitrofurantoin as a first-line option in relevant uncomplicated UTI settings.[4]
What drives the financial trajectory of nitrofurantoin macrocrystalline?
The product has a stable volume base but limited pricing power. Financial performance is determined by market structure rather than innovation.
Volume drivers
Demand is supported by:
- High prevalence of uncomplicated cystitis.
- Continued outpatient prescribing.
- Antimicrobial-stewardship preference for urinary-concentrating agents.
- Generic affordability.
- Recurring treatment and prophylaxis use in selected patients.
Price constraints
Revenue is constrained by:
- Multiple ANDA holders.
- Pharmacy-benefit-manager reimbursement pressure.
- Low generic acquisition prices.
- Therapeutic substitution with other antibiotics.
- Limited ability to differentiate the standard capsule.
- Lack of patent protection.
Supply-side risks
The most important earnings risk is supply disruption. Nitrofurantoin requires consistent API quality and particle-size control. A small number of active manufacturers at a particular time can create temporary shortages even when the overall market has many historical suppliers.
The FDA Drug Shortages database should be monitored for current availability conditions. Shortages can produce short-term price increases and share gains for manufacturers with inventory, but they do not establish durable market power.[5]
What is the revenue exposure for nitrofurantoin macrocrystalline?
Public companies generally do not report nitrofurantoin macrocrystalline revenue as a separate line item. The product is usually included within broader generic pharmaceuticals, oral solids or antimicrobial portfolios.
As a result, financial analysis should use proxy indicators:
| Metric |
Relevance |
| Prescription volume |
Measures underlying demand |
| Average selling price |
Measures generic price pressure |
| Manufacturer count |
Indicates fragmentation |
| Back-order and shortage data |
Measures supply tightness |
| API cost |
Indicates gross-margin sensitivity |
| Contract wins and formulary access |
Indicates share potential |
| Product discontinuations |
Signals low-margin portfolio rationalization |
For a diversified generic company, nitrofurantoin macrocrystalline is unlikely to be a material enterprise-value driver unless the company has concentrated exposure or benefits from a prolonged shortage. Its strategic value is more likely to be portfolio breadth and recurring volume than high-margin growth.
How strong is the patent estate for nitrofurantoin macrocrystalline?
The patent estate is weak for the conventional product and does not support a branded pricing strategy. A commercial assessment should assign greater weight to regulatory and manufacturing factors.
| Factor |
Strength |
| Core composition patent |
None of practical current value |
| Macrocrystalline form protection |
Historical, not a broad current barrier |
| Standard capsule protection |
Weak or expired |
| Method-of-use protection |
Limited |
| Manufacturing know-how |
Moderate operational value |
| FDA approval and quality systems |
Important market-access barrier |
| Supply reliability |
High commercial importance |
| Brand loyalty |
Low in the generic channel |
The strongest defensibility lies in reliable supply, validated API sourcing, regulatory compliance and wholesaler relationships. Those advantages are operational rather than patent-based.
What generic launch scenarios exist for nitrofurantoin macrocrystalline?
Base case: stable generic competition
Multiple suppliers maintain approval and availability. Prices remain low, volume tracks UTI incidence and the product generates modest recurring revenue.
Shortage-driven upside
One or more suppliers experience manufacturing or API problems. Available manufacturers gain temporary volume and pricing leverage. The effect can be meaningful for a small generic company but is unlikely to persist after supply normalizes.
Portfolio rationalization
Low margins cause a supplier to discontinue one or more strengths or package sizes. Remaining suppliers gain share, but the market remains price-sensitive.
Reformulation competition
A manufacturer launches a more convenient dosage form or improved delivery system. Such a product could command a premium if clinically differentiated, but it would compete more directly with nitrofurantoin monohydrate/macrocrystals than with the basic macrocrystalline capsule.
Does nitrofurantoin macrocrystalline face biosimilar risk?
No. Nitrofurantoin is a small-molecule antibacterial, not a biologic. Biosimilar competition is legally irrelevant. The competitive threat comes from ordinary ANDA-approved generics, alternative nitrofurantoin formulations and other oral UTI antibiotics.
What licensing deals affect nitrofurantoin macrocrystalline?
No major current licensing transaction is central to the conventional nitrofurantoin macrocrystalline market. The product is broadly genericized, and commercial rights are generally handled through supply, distribution or contract-manufacturing arrangements rather than high-value innovation licenses.
A licensing opportunity would be more plausible for:
- A novel sustained-release formulation.
- A pediatric or patient-friendly dosage form.
- A new delivery technology.
- A combination product.
- A differentiated product with clinical evidence supporting improved tolerability or adherence.
No such arrangement should be assumed to create value for the legacy macrocrystalline capsule without evidence of an active product or enforceable rights.
What geographic markets matter for nitrofurantoin macrocrystalline?
The United States remains commercially important because of its large outpatient prescription market and FDA-regulated generic supply chain. Europe, the United Kingdom, Canada and other regulated markets also use nitrofurantoin, but product naming, formulation availability, reimbursement and prescribing restrictions vary by jurisdiction.
Geographic barriers include:
- Separate regulatory approvals.
- Country-specific pharmacovigilance obligations.
- Local reimbursement controls.
- Different renal-function labeling.
- API and finished-dose import requirements.
- National tender pricing.
- Varying resistance patterns and guideline use.
U.S. patent expiry does not establish freedom to operate in every country. However, because the active ingredient and conventional formulation are old, the primary international barriers are regulatory and commercial rather than composition patents.
Key Takeaways
- Nitrofurantoin macrocrystalline is a mature, low-cost generic antibiotic used mainly for lower urinary tract infections.
- Macrodantin is the legacy macrocrystalline reference product; Macrobid is a separate monohydrate/macrocrystal formulation with twice-daily dosing.
- No material active U.S. patent barrier is expected for the conventional macrocrystalline capsule.
- Paragraph IV litigation and biosimilar risk are not central commercial issues.
- Formulation and method-of-use patents have limited relevance unless they protect a genuinely differentiated product.
- Revenue is driven by prescription volume, reimbursement and supply reliability, not patent pricing power.
- The principal upside is shortage-related share and pricing leverage.
- Manufacturing controls, API sourcing, dissolution performance and FDA compliance are more important than patent exclusivity.
- Public companies generally do not disclose nitrofurantoin macrocrystalline revenue separately.
- Long-term financial growth is likely to be modest unless a supplier develops a differentiated formulation or captures share during sustained supply disruption.
FAQs
Is nitrofurantoin macrocrystalline the same as Macrobid?
No. Nitrofurantoin macrocrystalline is the macrocrystal-only formulation associated with Macrodantin. Macrobid contains both nitrofurantoin monohydrate and macrocrystals and is generally dosed twice daily.[2]
Can a generic manufacturer launch nitrofurantoin macrocrystals without a Paragraph IV challenge?
Generally yes, where no applicable Orange Book-listed patent blocks approval. The product’s long history and established generic market make a conventional ANDA pathway more important than patent litigation.
Why can nitrofurantoin prices rise despite expired patents?
Prices can increase temporarily when API shortages, manufacturing failures, facility remediation or supplier exits reduce available inventory. These increases reflect supply concentration rather than patent exclusivity.
Is nitrofurantoin macrocrystalline suitable for kidney infections?
No. Nitrofurantoin is used for lower urinary tract infections and does not achieve adequate renal tissue concentrations for pyelonephritis.[1]
What would make a new nitrofurantoin product commercially valuable?
A new product would need a defensible clinical or formulation advantage, such as less frequent dosing, improved tolerability, broader usability in defined renal-function groups or a delivery system that supports premium reimbursement.
References
-
U.S. Food and Drug Administration. (n.d.). Macrodantin (nitrofurantoin macrocrystals) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (n.d.). Macrobid (nitrofurantoin monohydrate/macrocrystals) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., & Soper, D. E. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. Clinical Infectious Diseases, 52(5), e103-e120. https://doi.org/10.1093/cid/ciq257
-
U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
